執(zhí)照.jpg)
鵝去氧膽酸
分析標(biāo)準(zhǔn)品,HPLC≥98%
Chenodeoxycholic acid
CAS號：474-25-9
分子式：C24H40O4
分子量：392.58
MDL：MFCD00064142
別名：脫氧鵝膽酸；鵝脫氧膽酸；3α,7α-二羥基膽質(zhì)酸；3α,7α-二羥基-5-β-膽烷酸
貨號 | 規(guī)格/參數(shù)/品牌 | 價格 | 貨期 |
YJ-B20347-20mg | 分析標(biāo)準(zhǔn)品,HPLC≥98% | ￥350.00 | 現(xiàn)貨 |
JS25542-5g | 98% | ￥160.00 | 現(xiàn)貨 |
JS25542-25g | 98% | ￥270.00 | 現(xiàn)貨 |
JS25542-100g | 98% | ￥650.00 | 現(xiàn)貨 |
產(chǎn)品介紹
鵝去氧膽酸是一種疏水初級膽汁酸，能夠活化核受體 FXR，該受體與膽固醇代謝有關(guān)。 生物活性：
Chenodeoxycholic Acid 是一種疏水初級膽汁酸，能夠活化核受體 FXR，該受體與膽固醇代謝有關(guān)。鵝去氧膽酸（CDCA）和脫氧膽酸（DCA）均能抑制11 beta HSD2，IC50值分別為22mM和38mM，并引起皮質(zhì)醇依賴性核易位，增加鹽皮質(zhì)激素受體（MR）的轉(zhuǎn)錄活性。鵝去氧膽酸能夠通過激活膜G蛋白偶聯(lián)受體（TGR5）依賴途徑，誘導(dǎo)細(xì)胞周期蛋白d1蛋白和mRNA表達(dá)的顯著增加，從而刺激Ishikawa細(xì)胞的生長。鵝去氧膽酸（CDCA）在培養(yǎng)的人肝母細(xì)胞瘤細(xì)胞系HepG2中誘導(dǎo)低密度脂蛋白受體mRNA水平約為4倍，高密度脂蛋白輔酶A還原酶和高密度脂蛋白輔酶A合成酶的mRNA水平為2倍。氯去氧膽酸誘導(dǎo)的ISC（≥67%）被布美他尼、Bacl2和囊性纖維化跨膜電導(dǎo)調(diào)節(jié)器（CFTR）抑制劑cftrinh-172抑制。腺苷酸環(huán)化酶抑制劑MDL12330A使鵝去氧膽酸刺激的ISC降低43%，鵝去氧膽酸增加細(xì)胞內(nèi)cAMP濃度。鵝去氧膽酸處理激活c/ebpβ，如其磷酸化、核積累和在hepg2細(xì)胞中的表達(dá)增加所示。Chenodeoxycholic acid增強(qiáng)含有-1.65-kb GSTA2啟動子的構(gòu)建體的熒光素酶基因轉(zhuǎn)錄，該啟動子含有C / EBP反應(yīng)元件（pGL-1651）。鵝去氧膽酸處理激活AMP激活蛋白激酶（AMPK），導(dǎo)致細(xì)胞外信號調(diào)節(jié)激酶1/2（ERK1/2）激活，實(shí)驗(yàn)結(jié)果證明了使用AMPKα的顯性負(fù)突變體和化學(xué)抑制劑。
熔點(diǎn)：165-167℃
沸點(diǎn)：547.1 ℃ at 760 mmHg
比旋光度：12 o (c=1, CHCl3)
外觀：白色粉末
溶解性：幾乎不溶于水，易溶于乙醇、冰乙酸、微溶于氯仿。
敏感性：對光敏感
儲存條件：2-8℃
注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。
參考文獻(xiàn)(41篇)
41. [IF=3.1] Dan Yang et al."The defense role of luteolin-β-CD-MOF against acetaminophen induced liver toxicity by regulating of bile acids metabolism and gut microbiota."JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS.2025 Nov;265:117033
40. [IF=5.4] Yunhua Liu et al."Molecular Mechanisms of Potentilla Discolor Bunge in Regulating Ferroptosis to Alleviate DKD via the Nrf2 Signaling Pathway."JOURNAL OF ETHNOPHARMACOLOGY.2025 May;:120035
39. [IF=4.4] Yanruyu Feng et al."Integrative analysis of non12-hydroxylated bile acid revealed the suppressed molecular map of alternative pathway in nonalcoholic steatohepatitis mice."FASEB JOURNAL.2024 Nov;38(22):e70167
38. [IF=4.9] Donglin Du et al."Exploring the CDCA-Scd1 Axis: Molecular Mechanisms Linking the Colitis Microbiome to Neurological Deficits."INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.2025 Jan;26(5):2111
37. [IF=5.1] Yilong Liu et al."Myricetin alleviates high-fat diet-induced atherosclerosis in ApoE?/? mice by regulating bile acid metabolism involved in gut microbiota remodeling."Food & Function.2025 Mar;:
36. [IF=5.3] Tong Tian-Tian et al."Pharmacological effects of bile acids on polycystic ovary syndrome via the regulation of chemerin."Chinese Medicine.2025 Dec;20(1):1-19
35. [IF=3.2] Jingjing Lu et al."The adaptive mechanism of Ctenopharyngodon idellus to dietary lipid levels: Insights from microbiota-mediated bile acid enterohepatic circulation."Aquaculture Reports.2025 Jul;42:102796
34. [IF=6.9] Dongmei Qin et al."Lupeol improves bile acid metabolism and metabolic dysfunction-associated steatotic liver disease in mice via FXR signaling pathway and gut-liver axis."BIOMEDICINE & PHARMACOTHERAPY.2024 Aug;177:116942
33. [IF=5.4] Yingkun Sheng et al."Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway."JOURNAL OF ETHNOPHARMACOLOGY".2024 Apr;:118209
32. [IF=5.6] Dan Yang et al."Luteolin-β-CD-MOF prevents against acetaminophen-mediated liver damage by controlling ferroptosis through GSH/GPX4/SLC7A11 signal axis."Journal of Functional Foods".2024 May;116:106138
31. [IF=6.1] Shurui Zhang et al."Lactiplantibacillus plantarum ATCC8014 Alleviates Postmenopausal Hypercholesterolemia in Mice by Remodeling Intestinal Microbiota to Increase Secondary Bile Acid Excretion."JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY".2024;72(12):6236–6
30. [IF=4.9] Huang Hefei et al."Tanreqing injection inhibits dengue virus encephalitis by suppressing the activation of NLRP3 inflammasome."Chinese Medicine".2024 Dec;19(1):1-17
29. [IF=5.6] Shengyun Dai et al."Synergistic effect of Euphorbia kansui stir-fried with vinegar and bile acids on malignant ascites effusion through modulation of gut microbiota."Frontiers in Pharmacology.2023; 14: 1249910
28. [IF=3.9] Ya-nan Ou-Yang et al."High-salt diet induces dyslipidemia through the SREBP2/PCSK9 pathway in dahl salt-sensitive rats."BIOCHIMIE.2023 Oct;:
27. [IF=6.1] Sensen Chi et al."Time-restricted feeding alleviates metabolic implications of circadian disruption by regulating gut hormone release and brown fat activation."Food & Function.2023 Oct;:
26. [IF=7.9] Mei-Qi Wang et al."Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress."PHYTOMEDICINE.10.1016/j.phymed.2023.155124
25. [IF=4.6] Wei Li et al."Characterization of Metabolic Correlations of Ursodeoxycholic Acid with Other Bile Acid Species through In Vitro Sequential Metabolism and Isomer-Focused Identification."MOLECULES.2023 Jan;28(12):4801
24. [IF=4.212] Yingkun Sheng et al."PARP-1 inhibitor alleviates liver lipid accumulation of atherosclerosis via modulating bile acid metabolism and gut microbes."Molecular Omics.2023 May;:
23. [IF=6.911] Yan-Zhen Wang et al."A strategy for screening and identification of new amino acid-conjugated bile acids with high coverage by liquid chromatography-mass spectrometry."ANALYTICA CHIMICA ACTA.2023 Jan;1239:340691
22. [IF=7.675] Lei Xu et al."Chenodeoxycholic Acid (CDCA) Promoted Intestinal Epithelial Cell Proliferation by Regulating Cell Cycle Progression and Mitochondrial Biogenesis in IPEC-J2 Cells."Antioxidants.2022 Nov;11(11):2285
21. [IF=4.571] Yuanjie Wen et al."The role of the farnesoid X receptor in quadruple anti-tuberculosis drug-induced liver injury."TOXICOLOGY.2022 Jun;476:153256
20. [IF=6.558] Yan Cao et al."Widely quasi-quantitative analysis enables temporal bile acids-targeted metabolomics in rat after oral administration of ursodeoxycholic acid."ANALYTICA CHIMICA ACTA. 2022 Jun;1212:339885
19. [IF=5.396] Juan Wu et al."Sargassum fusiforme polysaccharide is a potential auxiliary substance for metformin in the management of diabetes."Food Funct. 2022 Feb;:
18. [IF=3.935] Runjing Zhang et al."Xiaoyan lidan formula ameliorates α-naphthylisothiocyanate-induced intrahepatic cholestatic liver injury in rats as revealed by non-targeted and targeted metabolomics."J Pharmaceut Biomed. 2020 Feb;179:112966
17. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180
16. [IF=3.935] Song Lin et al."A systemic combined nontargeted and targeted LC-MS based metabolomic strategy of plasma and liver on pathology exploration of alpha-naphthylisothiocyanate induced cholestatic liver injury in mice."J Pharmaceut Biomed. 2019 Jul;171:180
15. [IF=5.34] Kaihui Zhang et al."A UPLC-MS/MS-based metabolomics analysis of the pharmacological mechanisms of rabdosia serra against cholestasis."Phytomedicine. 2021 Oct;91:153683
14. [IF=5.396] Cong Liang et al."Lactiplantibacillus plantarum H-87 prevents high-fat diet-induced obesity by regulating bile acid metabolism in C57BL/6J mice."Food Funct. 2021 May;12(10):4315-4324
13. [IF=5.396] Shiming Huang et al."A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice."Food Funct. 2019 Jun;10(6):3224-3236
12. [IF=5.81] Shujing Lv et al."The Study on the Mechanism of Hugan Tablets in Treating Drug-Induced Liver Injury Induced by Atorvastatin."Front Pharmacol. 2021; 12: 683707
11. [IF=5.81] Li Peng et al."Detection of Vasodilators From Herbal Components by a Transcriptome-Based Functional Gene Module Reference Approach."Front Pharmacol. 2019 Oct;0:1144
10. [IF=3.935] Ziying Liu et al."Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowing effect of Si-miao-yong-an decoction: Application of LC–MS/MS method to determine 6 major bile acids in rat liver and plasma."J Pharmaceut Bio
9. 曹妍,李婷,常安琪,蔣珍珍,于娟,屠鵬飛,宋月林.蛇膽中膽汁酸類化學(xué)成分分析[J].中國中藥雜志,2021,46(01):130-138.
8. 李瑋,蔣珍珍,李菡,屠鵬飛,宋青青,于娟,宋月林.利用在線加壓溶劑提取-超高效液相色譜-離子阱-飛行時間-質(zhì)譜法定性分析片仔癀化學(xué)成分組[J].色譜,2021,39(05):478-487.
7. 曹妍, 宋青青, 李軍,等. 牦牛膽中膽汁酸類化學(xué)成分分析[J]. 中國中藥雜志 2019年44卷12期, 2538-2543頁, MEDLINE ISTIC PKU CSCD CA BP, 2019.
6. 陳云, 陳勁松, 郁紅禮,等. 膽南星發(fā)酵制品與混合蒸制品的鑒別研究[J]. 世界中醫(yī)藥, 2019, v.14(02):42-45+50.
5. 陳云 郁紅禮 吳皓 等. 發(fā)酵對膽南星中膽汁酸類成分的影響及膽南星中3種游離膽汁酸含量測定研究[J]. 中國中藥雜志 2018 43(22):99-103.
4. 陳江寧, 單國順, 劉曉瑜,等. 膽南星輔料成分分析及其清熱作用[J]. 中國現(xiàn)代中藥 2016年18卷7期, 837-840頁, ISTIC CA, 2016.
3. 席曉志, 李佳, 郭莎莎,等. 鵝去氧膽酸的大孔樹脂純化工藝優(yōu)化及其降血脂活性[J]. 現(xiàn)代食品科技, 2018, 034(008):123-129.
2. 趙啟苗, 單國順, 陳江寧,等. 膽南星質(zhì)量評價方法初探[J]. 中國實(shí)驗(yàn)方劑學(xué)雜志, 2017(06):28-31.
1. 陳江寧 單國順 趙啟苗 等. 不同膽汁制膽南星中膽酸類成分及其解熱作用比較[J]. 現(xiàn)代藥物與臨床 2017 32(004):567-571.
從2011年開始我們致力于在生命科學(xué)領(lǐng)域、生物醫(yī)學(xué)實(shí)驗(yàn)技術(shù)及論文潤色服務(wù)，協(xié)助客戶各類實(shí)驗(yàn)服務(wù)及論文潤色十余年，是客戶您值得信賴的科研合作伙伴!
如果您受時間、試驗(yàn)條件等限制而無法完成您的課題研究，歡迎您與我們聯(lián)系。
實(shí)驗(yàn)技術(shù)服務(wù)：
